Table 1.
List of ongoing clinical studies to evaluate CTCs in HCC patients after different interventions
| Participants | Intervention | Objective-result/status | NCT number | |
|---|---|---|---|---|
| 1 | 57 | TACE | A decrease in CTC count after surgery indicates that postoperative TACE is effective in preventing the recurrence of HCC/Completed | NCT02032368 |
| 2 | 220 | Propofol, Sevoflurane | Recruiting | NCT04601961 |
| 3 | 150 | 1.curative surgery or radiofrequency ablation therapy 2. TACE 3. systemic therapy | Recruiting | NCT01930383 |
| 4 | 184 | FOLFOX4(infusional FU, LV, and OXA) | Recruiting | NCT04521491 |
| 5 | 45 | Radiotherapy | Recruiting | NCT02066974 |
| 6 | 200 | Hepatic resection | Recruiting | NCT04800497 |
| 7 | 100 | Sorafenib | Completed | NCT01481805 |
| 8 | 300 | CTC Capture for early diagnosis and postoperative tumor recurrence monitoring of liver Cancer /Recruiting | NCT04688606 | |
| 9 | 37 | Durvalumab + SBRT | Recruiting | NCT04913480 |
| 10 | 50 | PD-1/ Sorafenib | Recruiting | NCT04152356 |
| 11 | 200 | Recruiting | NCT02036216 | |
| 12 | 256 | TACE/ Epirubicin/ lipiodol | Not yet recruiting | NCT02631499 |
| 13 | 40 | - | Recruiting | NCT04506398 |
| 14 | 20 | IRE & multiple NK immunotherapies | Completed | NCT03008343 |
| 15 | 167 | Sorafenib, RFA or surgery, Everolimus, Lanreotide | Completed | NCT02973204 |
| 16 | 25 | Temsirolimus | Recruiting | NCT01567930 |
| 17 | 18 | COMBIG-DC (ilixadencel) | Completed | NCT01974661 |